Sagimet Biosciences (SGMT) Projected to Post Quarterly Earnings on Monday

Sagimet Biosciences (NASDAQ:SGMT) is anticipated to issue its Q4 2025 resultson Monday, March 30th. Analysts expect the company to announce earnings of ($0.4322) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 7:00 AM ET.

Sagimet Biosciences (NASDAQ:SGMT) last posted its earnings results on Wednesday, March 11th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.14. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sagimet Biosciences Price Performance

NASDAQ SGMT opened at $4.89 on Friday. Sagimet Biosciences has a fifty-two week low of $1.73 and a fifty-two week high of $11.41. The stock’s 50-day moving average is $5.52 and its two-hundred day moving average is $6.45. The firm has a market cap of $159.32 million, a P/E ratio of -3.11 and a beta of 3.35.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Rodman & Renshaw assumed coverage on Sagimet Biosciences in a report on Thursday. They set a “buy” rating and a $28.00 price objective on the stock. Barclays started coverage on Sagimet Biosciences in a research report on Tuesday, January 27th. They set an “equal weight” rating and a $8.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Sagimet Biosciences in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Thursday, January 22nd. Finally, Guggenheim initiated coverage on shares of Sagimet Biosciences in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $27.00 price objective for the company. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Sagimet Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $26.25.

Insider Buying and Selling at Sagimet Biosciences

In related news, CEO David Happel sold 12,101 shares of the business’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $5.36, for a total transaction of $64,861.36. Following the completion of the transaction, the chief executive officer owned 677,621 shares of the company’s stock, valued at approximately $3,632,048.56. The trade was a 1.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 14.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SGMT. Geode Capital Management LLC boosted its position in shares of Sagimet Biosciences by 0.6% in the second quarter. Geode Capital Management LLC now owns 265,324 shares of the company’s stock valued at $2,023,000 after acquiring an additional 1,600 shares during the period. Landscape Capital Management L.L.C. grew its stake in shares of Sagimet Biosciences by 14.1% in the fourth quarter. Landscape Capital Management L.L.C. now owns 25,901 shares of the company’s stock worth $153,000 after acquiring an additional 3,198 shares during the last quarter. HighTower Advisors LLC increased its position in Sagimet Biosciences by 10.1% during the fourth quarter. HighTower Advisors LLC now owns 37,189 shares of the company’s stock worth $220,000 after acquiring an additional 3,408 shares during the period. American Century Companies Inc. raised its stake in Sagimet Biosciences by 8.9% during the 2nd quarter. American Century Companies Inc. now owns 42,285 shares of the company’s stock valued at $322,000 after purchasing an additional 3,454 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in Sagimet Biosciences by 819.2% during the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock valued at $29,000 after purchasing an additional 4,391 shares during the last quarter. 87.86% of the stock is owned by institutional investors.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.